Introduction
============

Graves' orbitopathy (GO) is an autoimmune disorder of the orbit, which is closely related to Graves' disease (GD).[@b1-opth-10-2277] Ophthalmic manifestations are present in 25%--50% of patients with GD, and the majority of patients with GO have already presented or are anticipated to experience Graves' hyperthyroidism.[@b1-opth-10-2277],[@b2-opth-10-2277] GO has an annual incidence rate of 16 women and 3 men per 100,000, principally affecting patients aged between 30 and 60 years old.[@b1-opth-10-2277] Although it is a self-limiting disease, 5% of patients have sight-threatening disease manifestations.[@b2-opth-10-2277]

Clinical assessment and treatment of GO remain a riddle for physicians of varied specialties.[@b3-opth-10-2277]--[@b5-opth-10-2277] Several clinical studies, over the last 60 years, have attempted to identify specific clinical and imaging parameters, sensitive enough to predict the progression of GO.[@b5-opth-10-2277],[@b6-opth-10-2277] However, a standardized clinical and imaging protocol for GO evaluation is lacking.

Various clinical scores were used for the assessment of the activity and severity of GO. The clinical activity score (CAS) was proposed in 1989 for the evaluation of GO activity.[@b7-opth-10-2277],[@b8-opth-10-2277] The modified NOSPECS (No clinical signs or symptoms, Only signs, Soft tissue involvement, Proptosis, Extraocular muscle involvement, Corneal involvement, Sight loss due to optic nerve compression) classification and total eye score (TES) have been proposed for the assessment of GO severity.[@b4-opth-10-2277],[@b9-opth-10-2277] Despite their undisputed usefulness, a limitation of these scores is that they are subjective and relatively nonspecific, as they are based on clinical examination.[@b8-opth-10-2277] In clinical practice, when more objective measurements are required, they are provided by magnetic resonance imaging (MRI), which is considered the most useful imaging technique for the evaluation of GO.[@b10-opth-10-2277] Specifically, short tau inversion recovery-sequence (STIR) MRI assesses the activity of GO, as it detects signs of inflammation and edema in the orbital tissues.[@b11-opth-10-2277]

In addition, treatment of GO also remains a challenging issue. Randomized trials and meta-analyses have established intravenous (IV) glucocorticoids (GCs) as the treatment of choice for active, moderate-to-severe GO.[@b4-opth-10-2277],[@b12-opth-10-2277]--[@b15-opth-10-2277] The most accepted dosage regimen that is currently in use, proposed by the European Group on GO (EUGOGO), is a 4.5 g cumulative dose of IV methylprednisolone (MP), administered in 12 weekly infusions.[@b4-opth-10-2277] However, an optimal treatment regimen providing effectiveness with minimal side effects and recurrences has not yet been established.[@b4-opth-10-2277],[@b6-opth-10-2277],[@b16-opth-10-2277],[@b17-opth-10-2277]

The aim of the present study was to evaluate the effectiveness and safety of an individualized treatment regimen consisting of a 12-week IV GC protocol, followed by oral GCs when needed, in patients with active, moderate-to-severe GO. Activity of GO was defined by the combination of clinical and imaging parameters.

Patients and methods
====================

Patients
--------

In total, 47 patients with untreated, active, moderate-to-severe GO were enrolled in the present study, according to the EUGOGO consensus statement.[@b5-opth-10-2277] The patients were examined between March 2009 and March 2015 at the Department of Endocrinology and Department of Ophthalmology in either the University Hospital of Larissa or in the University Hospital of Ioannina (Greece). This study was approved by the Ethics Committee of the University Hospital of Larissa, Greece, and all the patients included in this study signed an informed consent form.

Exclusion criteria were orbital disorders not related to GO and any form of strabismus present (ie, paralytic, comitant, or restrictive, caused by conditions other than GO). Patients with contraindications to steroid treatment were also excluded from this study.

Study design
------------

All the patients were subjected to complete ophthalmological examination and evaluated with CAS, NOSPECS, and TES before the initiation of IV GC treatment (baseline) and at 6, 12, and 24 weeks. They also had an orbital STIR MRI at baseline, 12 weeks, and 24 weeks. A Quality-of-Life (QoL) questionnaire was filled out by all the patients at baseline, 12 weeks, and 24 weeks.

All the patients received an IV cumulative dose of 4.5 g of MP within a period of 12 weeks as recommended by the EUGOGO,[@b4-opth-10-2277] that is, a course of 0.5 g of MP once weekly for 6 weeks followed by 0.25 g once weekly for 6 additional weeks. At the end of the IV treatment, patients with persistent active disease on clinical examination (CAS) or orbital imaging (STIR MRI) received additional GC treatment with oral prednisolone 30 mg daily, with a tapering period of 12 weeks (Group 1). Patients with inactive GO at the end of IV treatment received no further treatment (Group 2). All the patients who completed the treatment regimen were subjected to complete ophthalmological evaluation every 6 weeks, until 24 weeks after the end of treatment.

Patients with active GD received anti-thyroid medications in order to reach and maintain euthyroidism. Before initiation of IV treatment, patients with active hepatitis and tuberculosis had to be excluded from this study. All patients underwent blood tests for serum-free thyroxine (T4), free triiodothyronine (T3), thyroid-stimulating hormone (TSH), and anti-thyroid antibodies (ie, TRAb, anti- thyroglobulin, and anti-thyroperoxidase) at baseline and at regular intervals, according to their thyroid function status. Liver enzymes, blood glucose, and renal parameters were evaluated every 4 weeks during treatment. Smokers were assisted to quit smoking.

Ophthalmological examination
----------------------------

All the patients included in the study had a complete ophthalmological examination by the same ophthalmologist in each hospital. Soft tissue involvement, proptosis, corneal involvement, and eye muscle involvement were recorded. Severity of signs was graded with 0 (absent), 1 (minimal), 2 (moderate), or 3 (marked). The Color Atlas was used as a helpful tool for the identification of the grading.[@b18-opth-10-2277] Visual acuity, diplopia, and optic discs were assessed. Activity of GO was estimated by using the CAS,[@b7-opth-10-2277],[@b8-opth-10-2277] and severity of GO was evaluated by using the NOSPECS classification and its arithmetic expression, TES.[@b3-opth-10-2277],[@b5-opth-10-2277],[@b9-opth-10-2277]

Response to treatment during follow-up was defined as follows: change in CAS by at least two points was considered significant, and change of any of the NOSPECS signs by at least two grades was considered significant. For the assessment of the overall response to GC treatment, the definition of Bartalena et al was used, according to which improvement in at least two major criteria and one minor criterion is considered important. Major criteria include proptosis, diplopia, CAS, and visual acuity, and minor criteria are the soft tissue changes and self-assessment evaluation.[@b19-opth-10-2277]

MRI
---

MRI of the orbits included sagittal T1, axial and coronal T1 (repetition time \[TR\]: 813 ms, echo time \[TE\]: 12 ms, field of view \[FOV\]: 16×16, matrix: 320×256) and T2 (TR: 3,700 ms, TE: 100 ms, FOV: 16×16, matrix: 320×256) images. The MRI was performed on a 3T MRI scanner (HDxt GE scanner; GE Medical Systems, Waukesha, WI, USA). Axial images were obtained parallel to the optic nerve, and coronal images were obtained perpendicular to them. All images were obtained with slice thickness of 3 mm and 0.3 mm gap. Coronal STIR images (TR: 6,200 ms, TE: 46 ms, FOV: 16×16, matrix: 320×256) were also provided, in order to detect the presence of intramuscular edema.

QoL
---

QoL was evaluated using a disease-specific GO-QoL questionnaire proposed by EUGOGO, translated and validated in Greek. It included 16 questions that evaluate the performance of everyday activities in patients with GO: 8 questions referred to limitations in practicing usual activities, and the remaining 8 questions referred to the psychosocial limitations attributable to changes in appearance. Subsequently, for simplicity, questions were separated into two categories: those of visual function and those of psychosocial life. Patients completed the questionnaires based on their personal opinion over the course of the disease. Specifically, they graded convenience and desire in performing the reported activities, with higher scores expressing better QoL.

Statistical analysis
--------------------

Statistical analysis was conducted by using Statistical Package for Social Sciences Version 17 (SPSS Inc., Chicago, IL, USA). Baseline characteristics of the two groups were expressed as mean ± standard deviation or as counts and percentages, as appropriate. Comparisons between categorical data were done by using Fisher's exact test for independent samples and by using McNemar's test for dependent samples. Differences between continuous independent variables were tested using Mann--Whitney *U*-test. Comparison of measurements among dependent variables, over ≥3 time points, was done by one-way repeated measures analysis of variance with Bonferroni correction applied. The level of statistical significance was set at *P*\<0.05.

Results
=======

Patients
--------

In total, 47 patients with active, moderate-to-severe GO were enrolled in this study. They constituted of 18% of the total number of patients with GO (261), examined from March 2009 until March 2015 in the two centers. [Table 1](#t1-opth-10-2277){ref-type="table"} depicts demographic characteristics of all the patients, and age of these patients ranged from 32 to 81 years, with a mean age of 58.40±13.2 years. Of the 47 patients, 45 (95.8%) patients had a history of GD or were currently being treated for GD, 1 (2.1%) had no history or current thyroid dysfunction, and 1 (2.1%) had autoimmune hypothyroidism.

Of the 47 patients, 5 (10.6%) patients discontinued the IV GC treatment: 2 of them required urgent orbital decompression due to sight-threatening signs, and 3 patients presented major adverse events. The remaining 42 patients (89.4%) completed the IV GC treatment protocol. At the 12th week, of the 42 patients, 22 patients (52.4%; Group 1) had active GO as defined by clinical or imaging evaluation, and therefore, they received further oral treatment. The remaining 20 patients (47.6%; Group 2) had inactive disease and received no further treatment.

Clinical results
----------------

Overall response to GC treatment was observed in 32 (76.2%) of 42 patients at the 12th week and in 39 (92.8%) of 42 patients at the 24th week.

### CAS

A significant improvement in CAS was observed during the treatment period. The mean CAS decreased from 6.05±1.2 at baseline to 2.67±1.8 at the 12th week and 1.21±1.4 at the 24th week (*P*\<0.001; [Table S1](#SD1-opth-10-2277){ref-type="supplementary-material"}; [Figure 1A](#f1-opth-10-2277){ref-type="fig"}). At the 12th week, improvement in CAS was observed in 29 (69%) of 42 patients (*P*=0.001) and at the 24th week in 41 (97.6%) of 42 patients (*P*\<0.001; [Table S2](#SD2-opth-10-2277){ref-type="supplementary-material"}).

### TES

TES was significantly improved with treatment (*P*\<0.001; [Table S1](#SD1-opth-10-2277){ref-type="supplementary-material"}; [Figure 1B](#f1-opth-10-2277){ref-type="fig"}). Specifically, improvement in TES was observed in 28 (66.7%) of 42 patients at the 12th week (*P*=0.004) and in 38 (90.5%) of 42 patients at the 24th week (*P*=0.002). A deterioration of TES at the 12th week was evident in 7 (16.7%) of 42 patients, 6 (14.3%) of whom presented improvement after receiving the oral steroid regimen, at the 24th week ([Table S2](#SD2-opth-10-2277){ref-type="supplementary-material"}).

### QoL

[Tables S1](#SD1-opth-10-2277){ref-type="supplementary-material"} and [S2](#SD2-opth-10-2277){ref-type="supplementary-material"}, and [Figure 1C](#f1-opth-10-2277){ref-type="fig"} present QoL results. At baseline, QoL parameters were low, expressing a significant influence of QoL in both visual function and psychosocial life. Mean ± SD QoL visual function improved from 4.21±1.3 at baseline to 5.69±2.6 at the 12th week (*P*=0.005) and to 8.43±2.2 at the 24th week (*P*\<0.001). Mean ± SD QoL psychosocial life improved from 2.57±2.5 at baseline to 4.79±2.9 at the 12th week (*P*=0.001) and 7.19±3.0 (*P*\<0.001), all demonstrating significant improvement at both the 12th and 24th weeks ([Table S1](#SD1-opth-10-2277){ref-type="supplementary-material"}). At the 12th week, 28 (66.7%) of 42 patients had improvement in the QoL -- visual function and 23 (54.8%) of 42 patients had improvement in the QoL -- psychosocial life. At the 24th week, the number of patients presenting improvement reached 38 of 42 patients in the QoL-visual function and 36 of 42 patients in the QoL-psychosocial life component (90.5% and 85.7% respectively; [Table S2](#SD2-opth-10-2277){ref-type="supplementary-material"}).

### Ophthalmic evaluation

At baseline visit, soft tissue signs were present in 42 (100%) of 42 patients, exophthalmos in 35 patients (83.3%), ocular motility dysfunction in 36 patients (85.7%), and corneal involvement in 22 (52.4%) of patients. At the end of the 24th week, the aforementioned features were either minimal or absent in the majority of treated patients (90.5%, 83.3%, 78.6%, and 100% of patients respectively; [Table S3](#SD3-opth-10-2277){ref-type="supplementary-material"}). The improvement in clinical signs over time was significant at the 24th week, as depicted in [Figure 2](#f2-opth-10-2277){ref-type="fig"}.

### Administration of additional oral steroids and comparison between the two groups

Oral steroids were administered at patients who continued to present active GO at the end of IV treatment (at the 12th week). At that point, as it is expected, CAS was significantly higher in Group 1 (*P*=0.002). At the 24th week, CAS did not present statistically significant difference between the two groups (*P*=0.157; [Table S4](#SD4-opth-10-2277){ref-type="supplementary-material"}; [Figure 3A](#f3-opth-10-2277){ref-type="fig"}). For both the groups, statistically significant reduction in CAS was observed at the 12th and 24th weeks (*P*\<0.001).

Mean TES did not present statistically significant difference between the two groups neither at the 12th week nor at the 24th week (*P*=0.685 and *P*=0.856, respectively; [Table S4](#SD4-opth-10-2277){ref-type="supplementary-material"}; [Figure 3B](#f3-opth-10-2277){ref-type="fig"}). For Group 1, statistically significant improvement in TES was not observed at the 12th week (*P*=0.185), but it was observed at the 24th week (*P*=0.001). For Group 2, statistically significant decrease in TES was observed at the 12th and 24th weeks (*P*\<0.001 and *P*=0.001, respectively).

[Table S4](#SD4-opth-10-2277){ref-type="supplementary-material"} and [Figure 3C and D](#f3-opth-10-2277){ref-type="fig"} show the comparison of the components of QoL between the two groups. For Group 1, statistically significant increase in visual function -- QoL was not observed at the 12th week (*P*=0.429), but it was observed at the 24th week (*P*\<0.001). For Group 2, statistically significant improvement in visual function-QoL was observed at the 12th and 24th weeks (*P*=0.003 and *P*\<0.001, respectively). As far as psychosocial life-QoL is concerned, both the groups had a significant improvement at the 24th week (Group 1: *P*\<0.001; Group 2: *P*\<0.001).

Demographic characteristics, smoking habits, disease duration, and family history did not present statistically significant difference between Groups 1 and 2 ([Table 2](#t2-opth-10-2277){ref-type="table"}).

### MRI

At the end of the IV treatment (12 weeks), STIR MRI demonstrated that 22 of the 42 patients presented persisting active inflammation. At that point, CAS revealed activity in 16 of 42 patients, all of which presented activity with the MRI. Patients with active GO at 12 weeks, ascertained by MRI or clinical examination, formed Group 1 (22 patients). At 24 weeks, STIR MRI and CAS demonstrated active GO in 1 of the 42 patients who completed the study.

### Surgery

Urgent orbital decompression surgery was performed in 2 (4.2%) of 47 patients, due to accelerating dysthyroid optic neuropathy (DON), early at the treatment period (before the 6th week of treatment). A type of rehabilitative surgery was performed in 3 (7.1%) of the 42 patients who received treatment after they had completed the full treatment scheme ([Table 3](#t3-opth-10-2277){ref-type="table"}).

### Recurrence

In total, 4 of the 42 patients had recurrence of GO up to 24 weeks after the completion of treatment ([Table 3](#t3-opth-10-2277){ref-type="table"}). The recurrence rate did not present a significant difference between the two groups (*P*\>0.999).

### Nonresponders

As mentioned previously, 2 (4.2%) of the initial 47 patients presented accelerating DON, although they were under treatment with IV GCs ([Table 3](#t3-opth-10-2277){ref-type="table"}). These patients were withdrawn from the treatment protocol before completing 6 weeks of treatment. In addition, at the 24th week, 1 patient (2.4%) presented aggravated GO and was subjected to additional IV GC treatment, after which the patient improved.

### Adverse events

IV GC treatment had to be discontinued in 3 of 47 patients due to adverse events: 1 patient had Herpes Zoster infection, and 2 developed severe electrolyte disturbances. Mild adverse events occurred during oral GC treatment ([Table 3](#t3-opth-10-2277){ref-type="table"}).

Discussion
==========

GCs have been the most common therapeutic option for active, moderate-to-severe GO with the IV administration being more effective and safe compared to the oral.[@b12-opth-10-2277],[@b13-opth-10-2277],[@b20-opth-10-2277]--[@b24-opth-10-2277] The broadly accepted dosage regimen, recommended by EUGOGO, consists of a 4.5 g cumulative dose of IV MP. However, certain patients do not respond to treatment at all, some patients have persistent active disease, or some may relapse after the completion of therapy, although they had an initial positive responce.[@b4-opth-10-2277],[@b6-opth-10-2277],[@b13-opth-10-2277] The current study suggested that the introduction of an additional oral GC regimen in specific patients enhances the therapeutic result. This personalized regimen seems to be effective and relatively safe and improves QoL. In addition, in this study, STIR MRI was an essential tool for the evaluation of GO activity, apart from clinical assessment.

At the end of the IV GC treatment, the overall response observed in the present study is consistent with previous reports that have used the same 12-week IV MP treatment scheme. The latter show an overall response rate of 35%--80% and CAS improvement of 64.1%--83%.[@b6-opth-10-2277],[@b13-opth-10-2277],[@b14-opth-10-2277],[@b25-opth-10-2277],[@b26-opth-10-2277] Nevertheless, with the addition of oral GC treatment in the present study, for patients with persistent active disease, the overall response rate and the CAS improvement increased remarkably, reaching 92.8% and 97.6% of patients, respectively.

Clinical evaluation of GO activity by using the CAS is a useful method, but it lacks accuracy and objectivity. Mourits et al defined specificity and sensitivity of clinical evaluation of activity of GO, with the use of CAS. They estimated specificity of 86% and sensitivity of 55%, showing that CAS alone could not detect active GO adequately.[@b8-opth-10-2277],[@b27-opth-10-2277],[@b28-opth-10-2277] Therefore, an imaging technique could supplement the clinical data allowing a more accurate assessment of disease activity.[@b10-opth-10-2277],[@b27-opth-10-2277],[@b29-opth-10-2277]--[@b32-opth-10-2277] STIR MRI is the method of choice for orbital imaging in GO. It is reliable in detecting active inflammation of orbital tissues in GO.[@b11-opth-10-2277],[@b33-opth-10-2277]--[@b39-opth-10-2277] STIR MRI is essential for supporting clinical diagnosis of GO, identifying disease phase and severity, assessing indication for treatment, and following response to treatment.[@b38-opth-10-2277] Recently, numerous studies have demonstrated that STIR MRI establishes activity of GO with more sensibility and reproducibility than CAS alone.[@b11-opth-10-2277],[@b38-opth-10-2277],[@b39-opth-10-2277] Specifically, they found that patients with low CAS could have remarkable inflammation of the extraocular muscles in the STIR MRI, a phenomenon similar to that demonstrated in the present study. Thus, combining clinical CAS with orbital STIR MRI could improve accuracy in detecting GO activity and is of great clinical importance.[@b11-opth-10-2277],[@b38-opth-10-2277],[@b39-opth-10-2277]

Relapse rate observed in the present study was 9.5%, which is lower compared to 21% and 43% of recurrences observed in previous studies.[@b6-opth-10-2277],[@b26-opth-10-2277] Bartalena et al conclude that recurrence of GO after the initial improvement, even for patients who received large doses of GCs (7.5 g of MP in 12 weeks), is probably caused by the abrupt steroid withdrawal, and proposes oral GC tapering, although the evidence for this until now was lacking.[@b6-opth-10-2277] In the present study, oral GC tapering treatment was continued in patients with persistent active disease after the IV steroid treatment, and it was believed that this resulted in the lower observed relapse rate.

A lower rate of side effects was observed in the present study, compared to other studies that analyze steroid treatment for GO.[@b6-opth-10-2277],[@b13-opth-10-2277],[@b21-opth-10-2277] The relatively low dose of oral GCs that has been used in a reducing manner resulted in only minor side effects, such as mild weight gain and subtle Cushingoid features. Severe adverse events, which led to interruption of IV GC treatment, were present at 6.4% of the patients, a smaller percentage compared to that of previous studies[@b15-opth-10-2277]--[@b17-opth-10-2277] and similar to that observed in the study by Bartalena et al.[@b6-opth-10-2277]

The lack of response to GC therapy is an important issue in the management of patients with GO. Previous studies reported a varying nonresponse rate between 8% and 65% at the end of the specific 12-week IV GC regimen, possibly due to the variety of criteria used by each study for the evaluation of response to treatment.[@b6-opth-10-2277],[@b13-opth-10-2277],[@b21-opth-10-2277],[@b25-opth-10-2277],[@b26-opth-10-2277] In the studies by Bartalena et al[@b6-opth-10-2277] and Zhu et al,[@b25-opth-10-2277] the clinical parameters of NOSPECS and CAS were used for the evaluation of response to treatment, similarly to the present study. However, in addition to the clinical parameters, the MRI findings were used to evaluate response to treatment, for a more objective evaluation. Bartalena et al reported 6% of patients developing DON during the first 12 weeks, and an additional 6% of patients developing DON between the 12th and 24th weeks. Zhu et al reported that 7.7% of patients received a second run of therapy within 6 months of the IV treatment.[@b6-opth-10-2277],[@b25-opth-10-2277] Nonresponse rate in the present study was lower (4.2%), and these patients developed accelerating DON during the first 6 weeks of IV steroids and required urgent orbital decompression. Aggravation of GO after 24 weeks of treatment was diagnosed in an additional 2.4% of the patients, but no DON was present, and they all improved after an additional IV GC scheme.

QoL is a useful tool for assessing response to therapy. In the present cohort, at the end of the IV treatment, patients in the group of persistent active disease presented low QoL scores, supporting the necessity for further treatment. After the 24th week of treatment, QoL scores were similar in both the groups. The aggregate of the patients in the present study presented a marked improvement in both aspects of QoL questionnaires at the end of treatment (visual component, 90.5%; and psychosocial component, 85.7%). Both the percentages were higher compared to previous studies (48%--81%), which could be explained by the fact that in the present study, the overall response rate is higher, with fewer relapses and side effects.[@b6-opth-10-2277],[@b13-opth-10-2277],[@b21-opth-10-2277]

Previous studies have indicated that the demographic factors, smoking, age, and sex might have a significant role in the response to steroid treatment in patients with GO.[@b4-opth-10-2277],[@b6-opth-10-2277],[@b38-opth-10-2277],[@b40-opth-10-2277] In the present study no such factors were found to affect the response to treatment and the clinical course of the disease in the two groups. Bartalena et al also found no effect of baseline characteristics such as age, sex, smoking history, and duration of GO.[@b6-opth-10-2277] Kahaly et al,[@b13-opth-10-2277] on the other hand, reported that patients with GO aged \<50 years and female patients respond better to IV and oral steroids, also that heavy smokers presented deterioration in their treatment. However, they did not compare the influence of the above factors between the different study groups.[@b13-opth-10-2277]

A limitation of the present study was the relatively small number of patients enrolled, but the strict inclusion criteria and the low incidence of the disease made it extremely difficult to include more patients over a reasonable time period. Another limitation is that patients who had additional treatment with oral GCs have not been chosen randomly. This would have posed an ethical dilemma as patients with active disease could not be left without any treatment. Finally, the continuous improvement in GO signs (eg, CAS, TES, and QoL score) in Group 2, after the termination of IV GC treatment, could also be considered a limitation of the present study. It is well accepted that IV steroids in patients with GO continue to produce positive results for a time period after the treatment is complete.[@b41-opth-10-2277] This fact is associated with the known tendency of GO to improve spontaneously.[@b42-opth-10-2277] However, there is no way to predict in which patients the positive response will continue and which patients will relapse.[@b41-opth-10-2277] Hence, the indicator for additional oral GC treatment used in the present study was persisting activity of GO at the end of IV GC treatment, recognized with the use of clinical and imaging parameters. The favorable results of the present study, combining high efficacy and low relapse rates, suggest that the decision in the treatment regimen was rather positive. However, additional studies are mandatory for a definitive conclusion, preferably, using a personalized therapeutic approach.

Our findings suggest that a combination of IV GC administration, followed by oral steroid treatment in selected patients, offers satisfactory effectiveness with relatively low rates of adverse events and recurrences. Close clinical monitoring and STIR MRI help to reveal those patients who need additional oral GC treatment. Such a demanding treatment and follow-ups, given also the scarcity of the disease, should be administered in specialized centers with appropriate expertise and input of multidisciplinary teams.

Supplementary materials
=======================

###### 

Mean values of CAS and TES at baseline and at 6-, 12-, and 24-week evaluation. Mean values of the parameters of QoL questionnaire (visual function and psychosocial life) at baseline and at 12-, and 24-week evaluation

                       Baseline      6th week      12th week     24th week    *P*-value                       
  -------------------- ------------- ------------- ------------- ------------ ----------- --------- --------- ---------
  CAS                  6.05±1.229    4.24±1.246    2.67±1.803    1.21±1.440   \<0.001     \<0.001   \<0.001   \<0.001
  TES                  17.55±5.478   16.33±7.479   13.02±6.759   8.33±6.603   \<0.001     \<0.001   0.003     0.638
  GO-QoL score                                                                                                
   Visual function     4.21±1.260                  5.69±2.646    8.43±2.154   \<0.001     0.005     \<0.001   
   Psychosocial life   2.57±2.500                  4.79±2.926    7.19±2.998   \<0.001     0.001     \<0.001   

**Note:** Values are expressed mean ± standard deviation, and *P*-values are calculated by using one-way ANOVA (Bonferroni correction).

**Abbreviations:** ANOVA, analysis of variance; CAS, clinical activity score; GO, Graves' orbitopathy; QoL, Quality-of Life questionnaire; TES, total eye score.

###### 

Evaluation of change in CAS and TES at the 6th, 12th, and 24th weeks and change in score (GO-QoL score) of Quality-of-Life questionnaire parameters (visual function and psychosocial life) at the 12th and 24th weeks

                       6 weeks % (n=42)   12 weeks % (n=42)   24 weeks % (n=42)   *P*-value   
  -------------------- ------------------ ------------------- ------------------- ----------- ---------
  CAS                                                                                         
   Improved            42.9 (18)          69 (29)             97.6 (41)           \<0.001     0.001
   Unchanged           52.4 (22)          26.2 (11)           0 (0)               --          0.007
   Deteriorated        4.8 (2)            4.8 (2)             2.4 (1)             \>0.999     \>0.999
  TES                                                                                         
   Improved            35.7 (15)          66.7 (28)           90.5 (38)           0.002       0.004
   Unchanged           42.9 (18)          16.7 (7)            7.1 (3)             0.219       0.027
   Deteriorated        21.4 (9)           16.7 (7)            2.4 (1)             0.031       0.754
  GO-QoL score                                                                                
   Visual Function                                                                            
    Improved                              66.7 (28)           90.5 (38)           0.021       
    Unchanged                             14.3 (6)            7.1 (3)             0.687       
    Deteriorated                          19 (8)              2.4 (1)             0.031       
   Psychosocial life                                                                          
    Improved                              54.8 (23)           85.7 (36)           0.001       
    Unchanged                             38.1 (16)           11.9 (5)            0.007       
    Deteriorated                          7.1 (3)             2.4 (1)             0.500       

**Note:** *P*-values are calculated using McNemar's test.

**Abbreviations:** CAS, clinical activity score; GO, Graves' orbitopathy; QoL, Quality-of-Life questionnaire; TES, total eye score.

###### 

Features of ophthalmic evaluation (soft tissue signs, exophthalmos, ocular motility, and corneal signs) at baseline and at 6-, 12- and 24-week evaluation

  --------------------------------------------------------------------------------------------------------------
  Ophthalmic evaluation   Baseline %\   6 weeks %\   12 weeks %\   24 weeks %\   *P*-value             
                          (n=42)        (n=42)       (n=42)        (n=42)                              
  ----------------------- ------------- ------------ ------------- ------------- ----------- --------- ---------
  Soft tissue signs                                                                                    

   Absent                 0             4.8 (2)      16.7 (7)      33.3 (14)     --          --        0.008

   Minimal                23.8 (10)     50 (21)      54.8 (23)     57.1 (24)     \<0.001     \<0.001   \>0.999

   Moderate               57.1 (24)     35.7 (15)    26.2 (11)     4.8 (2)       \<0.001     \<0.001   0.004

   Marked                 19 (8)        9.5 (4)      2.4 (1)       4.8 (2)       0.031       0.016     \>0.999

  Exophthalmos                                                                                         

   Absent                 16.7 (7)      14.3 (6)     21.4 (9)      40.5 (17)     0.002       0.500     0.008

   Minimal                42.9 (18)     50 (21)      54.8 (23)     42.9 (18)     \>0.999     0.063     0.063

   Moderate               38.1 (16)     31 (13)      21.4 (9)      14.3 (6)      0.002       0.016     0.250

   Marked                 2.4 (1)       4.8 (2)      2.4 (1)       2.4 (1)       \>0.999     \>0.999   \>0.999

  Ocular motility                                                                                      

   Absent                 14.3 (6)      11.9 (5)     14.3 (6)      31 (13)       0.016       \>0.999   0.016

   Minimal                31 (13)       40.5 (17)    54.8 (23)     47.6 (20)     0.016       0.002     0.250

   Moderate               45.2 (19)     38.1 (16)    23.8 (10)     16.7 (7)      \<0.001     0.004     0.250

   Marked                 9.5 (4)       9.5 (4)      7.1 (3)       4.8 (2)       0.500       \>0.999   \>0.999

  Corneal signs                                                                                        

   Absent                 47.6 (20)     52.4 (22)    69 (29)       81 (34)       \<0.001     0.004     0.063

   Minimal                52.4 (22)     38.1 (16)    28.6 (12)     19 (8)        \<0.001     0.002     0.125

   Moderate               0             9.5 (4)      2.4 (1)       0             --          --        --

   Marked                 0             0            0             0             --          --        --
  --------------------------------------------------------------------------------------------------------------

**Note:** *P*-values are calculated by using McNemar's test.

###### 

Comparison of CAS and TES between Groups 1 and 2, at baseline and 6th, 12th, and 24th weeks and of Quality-of-Life questionnaire (GO-QoL score) parameters between Groups 1 and 2 at baseline and at 12th and 24th weeks

                       Group 1 (subsequent oral GC)   Group 2 (not subsequent oral GC)   *P*-value
  -------------------- ------------------------------ ---------------------------------- -----------
  CAS                                                                                    
   Baseline            6.14±1.037                     5.95±1.432                         0.853
   6 weeks             4.41±1.368                     4.05±1.099                         0.314
   12 weeks            3.50±2.018                     1.75±0.910                         0.002
   24 weeks            1.59±1.764                     0.80±0.834                         0.157
  TES                                                                                    
   Baseline            16.55±5.405                    18.65±5.480                        0.332
   6 weeks             16.05±8.080                    16.65±6.953                        0.779
   12 weeks            13.45±7.443                    12.55±6.074                        0.685
   24 weeks            9.18±8.500                     7.40±3.530                         0.856
  GO-QoL score                                                                           
   Visual function                                                                       
    Baseline           4.27±1.453                     4.15±1.040                         0.795
    12 weeks           4.95±2.236                     6.50±2.875                         0.018
    24 weeks           8.09±2.448                     8.80±1.765                         0.358
   Psychosocial life                                                                     
    Baseline           2.50±2.559                     2.65±2.498                         0.746
    12 weeks           4.86±2.624                     4.70±3.294                         0.422
    24 weeks           6.91±2.942                     7.50±3.103                         0.889

**Notes:** Values are expressed as mean ± standard deviation. *P*-values are calculated by using Mann--Whitney *U*-test.

**Abbreviations:** CAS, clinical activity score; GC, glucocorticoids; GO, Graves' orbitopathy; QoL, Quality-of-Life questionnaire; TES, total eye score.
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![(**A**) Mean ± SD CAS at baseline and at 6-, 12-, and 24-week evaluation, (**B**) mean ± SD TES at baseline and at 6-, 12-, and 24-week evaluation, and (**C**) mean ± SD of scores of Quality-of-Life questionnaire parameters (visual function and psychosocial life) at baseline and 12- and 24-week evaluation.\
**Notes:** There is statistically significant improvement in all scores over the treatment period. Numbers over the bars represent the mean ± SD. Numbers above the bars represent the *P*-values. *P*-values are comparisons among treatment periods.\
**Abbreviations:** CAS, clinical activity score; TES, total eye score; SD, standard deviation.](opth-10-2277Fig1){#f1-opth-10-2277}

![Number of patients expressing improvement in clinical signs (eg, soft tissue signs, exophthalmos, ocular motility, and corneal signs) at 6-, 12-, and 24-week evaluation. **Notes:** Numbers above the bars represent the *P*-values. *P*-values are comparisons among treatment periods.](opth-10-2277Fig2){#f2-opth-10-2277}

![Mean values of CAS (**A**) and TES (**B**) at Groups 1 and 2, at baseline and at 6-, 12-, and 24-week evaluation; and mean values of the two parameters of Quality-of-Life questionnaire -- visual function (**C**) and psychosocial life (**D**) at Groups 1 and 2, at baseline and at 12- and 24-week evaluation.\
**Notes:** The black line represents patients who received additional oral GC treatment (Group 1), and the gray line represents patients who did not receive oral GC treatment (Group 2). Numbers over the bars represent the *P*-values. *P*-values are comparisons between the two groups.\
**Abbreviations:** CAS, clinical activity score; GC, glucocorticoid; TES, total eye score.](opth-10-2277Fig3){#f3-opth-10-2277}

###### 

Baseline characteristics

  Demographic characteristics             Total (n=47)
  --------------------------------------- -----------------------------------------------------------
  Age (years)                             58.40±13.235[a](#tfn1-opth-10-2277){ref-type="table-fn"}
  Sex (female)                            70.2% (33/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
  Smoking history                         
   Current smoker                         38.3% (18/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   Ex-smoker                              21.3% (10/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   Never-smoker                           40.4% (19/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
  History of thyroid disease              
   Graves' disease                        95.8% (45/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   Euthyroid                              2.1% (1/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   Hashimoto                              2.1% (1/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
  Previous thyroid treatments             
   Anti-thyroid drugs                     91.5% (44/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   Radioiodine                            0
   Thyroidectomy                          6.4% (3/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
  Current thyroid treatments              
   Levothyroxine and methimazole          48.9% (23/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   Levothyroxine only                     17.1% (8/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   Methimazole only                       31.9% (15/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
   None                                   2.1% (1/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
  Duration of eye symptoms (months)       12.09±13.118[a](#tfn1-opth-10-2277){ref-type="table-fn"}
  Duration of Graves' disease (months)    47.47±92.202[a](#tfn1-opth-10-2277){ref-type="table-fn"}
  Family history of Graves' disease       46.8% (22/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}
  Family history of Graves' orbitopathy   19.2% (9/47)[b](#tfn2-opth-10-2277){ref-type="table-fn"}

**Notes:**

Mean value ± standard deviation;

Proportions (n).

###### 

Comparison of parameters that might influence the course of Graves' orbitopathy between Groups 1 and 2

                                                   Group 1 (n=22)   Group 2 (n=20)   *P*-value
  ------------------------------------------------ ---------------- ---------------- ---------------------------------------------------
  Age (years)                                      60.091±13.822    55.85±11.895     0.231[b](#tfn5-opth-10-2277){ref-type="table-fn"}
  Sex (male/female)                                5/17             6/14             0.730[a](#tfn4-opth-10-2277){ref-type="table-fn"}
  Smokers (yes/no)                                 14/8             11/9             0.754[a](#tfn4-opth-10-2277){ref-type="table-fn"}
  Graves' disease duration (months)                45.454±76.867    43.400±67.356    0.355[b](#tfn5-opth-10-2277){ref-type="table-fn"}
  Graves' orbitopathy duration (months)            14.409±14.318    11.300±12.966    0.415[b](#tfn5-opth-10-2277){ref-type="table-fn"}
  Family history of Graves' disease (yes/no)       13/9             8/12             0.354[a](#tfn4-opth-10-2277){ref-type="table-fn"}
  Family history of Graves' orbitopathy (yes/no)   7/15             2/18             0.135[a](#tfn4-opth-10-2277){ref-type="table-fn"}

**Notes:** Values are expressed as mean ± standard deviation, or n. *P*-values from

Fisher's exact test and

Mann--Whitney *U*-test.

###### 

Nonresponders and recurrences after steroid treatment, surgical interventions, and adverse events of intravenous and oral steroid treatment in Groups 1 and 2

                                                    Total % (n)    Group 1 % (n)   Group 2 % (n)   *P*-value
  ------------------------------------------------- -------------- --------------- --------------- -----------
  Completion of steroid treatment                   89.4 (42/47)                                   
  Additional intravenous scheme (nonresponders)     2.4 (1/42)                                     
  Recurrences                                       9.5 (4/42)     9.1 (2/22)      10 (2/20)       \>0.999
  Surgical interventions                                                                           
   Urgent orbital decompression                     4.2 (2/47)                                     
  Surgeries after completion of steroid treatment                                                  
   Strabismus surgery                               4.2 (2/47)     4.5 (1/22)      5 (1/20)        0.598
   Eyelid surgery                                   2.1 (1/47)     4.5 (1/22)      0               
  Adverse events                                                                                   
   Intravenous steroids                                                                            
   Herpes Zoster infection                          2.1 (1/47)                                     
   Hypokalemia                                      4.2 (2/47)                                     
   Oral steroids                                                                                   
   Mild Cushingoid features                                                        22.7 (5/22)     
   Mild weight gain                                                                22.7 (5/22)     

**Note:** *P*-values from Fisher's exact test.
